Antiresorptive Therapies for Osteoporosis
- 1 November 2015
- journal article
- review article
- Published by Elsevier in Oral and Maxillofacial Surgery Clinics of North America
- Vol. 27 (4) , 555-560
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisBone, 2008
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Bone Quality — The Material and Structural Basis of Bone Strength and FragilityNew England Journal of Medicine, 2006
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal WomenJAMA, 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- A tale of two worlds in prescribing etidronate for osteoporosisThe Lancet, 1997
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996